You are here

Long-Acting Regimen of Cabotegravir and Rilpivirine Shows Sustained Virological Response and Good Tolerability in Patients with HIV

Injectable Combination Reduces Number of Annual Doses from 365 to 12

The injectable two-drug regimen of cabotegravir and rilpivirine (ViiV Healthcare, Brentford, England) could provide an alternative to daily tablets for patients with HIV, reducing the number of annual doses from 365 to 12.

Data from the LATTE-2 clinical trial showed durable treatment effects. At 160 weeks, 90% (n = 104/115) of patients who received the regimen every eight weeks and 83% (n = 95/115) of patients who received the regimen every four weeks remained virally suppressed. Patients in the oral comparator arm who switched to the injectable regimen at week 96 showed viral suppression rates of 97% (n = 33/34) and 100% (n = 10/10), respectively.

The most common adverse events included nasopharyngitis (38%), diarrhea (22%), and headache (22%). A majority of participants reported an injection-site reaction (ISR), 85% mild and 14% moderate, through week 160. Eighty-seven percent of ISRs resolved within seven days.

Sources: Seeking Alpha, October 29, 2018; ViiV Healthcare, October 30, 2018

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time